Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Larimar Therapeutics (LRMR) Interest Expenses (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Interest Expenses for 6 consecutive years, with $362000.0 as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Interest Expenses fell 27.45% year-over-year to $362000.0, compared with a TTM value of $1.8 million through Dec 2019, down 6.95%, and an annual FY2019 reading of $1.8 million, down 6.95% over the prior year.
  • Interest Expenses was $362000.0 for Q4 2019 at Larimar Therapeutics, down from $426000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $500000.0 in Q1 2019 and bottomed at $8000.0 in Q4 2017.
  • Average Interest Expenses over 5 years is $258200.0, with a median of $206500.0 recorded in 2015.
  • The sharpest move saw Interest Expenses soared 10550.0% in 2015, then tumbled 91.75% in 2017.
  • Year by year, Interest Expenses stood at $180000.0 in 2015, then plummeted by 46.11% to $97000.0 in 2016, then crashed by 91.75% to $8000.0 in 2017, then soared by 6137.5% to $499000.0 in 2018, then fell by 27.45% to $362000.0 in 2019.
  • Business Quant data shows Interest Expenses for LRMR at $362000.0 in Q4 2019, $426000.0 in Q3 2019, and $478000.0 in Q2 2019.